Mild COVID-19 infection associated with post-COVID-19 condition after 3 months - a questionnaire survey.

COVID-19 Long COVID SARS-CoV-2 cross-sectional population-based post-COVID-19 condition

Journal

Annals of medicine
ISSN: 1365-2060
Titre abrégé: Ann Med
Pays: England
ID NLM: 8906388

Informations de publication

Date de publication:
12 2023
Historique:
medline: 21 6 2023
pubmed: 20 6 2023
entrez: 20 6 2023
Statut: ppublish

Résumé

The coronavirus disease 2019 (COVID-19), caused by infection with SARS-CoV-2, can lead to post-COVID-19 condition, a secondary syndrome of persistent and new post-acute symptoms, but evidence on this syndrome is still scarce. In a questionnaire survey, residents of the city of Bremen (Germany) with verified SARS-CoV-2 infection were invited to answer questions (online questionnaire or interview) concerning symptoms experienced at the time of infection and at the time of questionnaire completion at least three months later. Main outcome of the analysis was the presence of a post-COVID-19 condition at the time of the interview, defined as the presence of at least two of three leading symptoms: fatigue, breathing difficulties, or cognitive problems. A post-COVID-19 condition was more likely to be reported if respondents had, at the time of infection, suffered from fatigue (OR 1.75; 95% CI: 1.00, 3.06), breathing difficulties (OR 4.02; 95% CI: 2.80, 5.77), cognitive symptoms (OR 2.98; 95% CI: 1.48, 6.02), or head- & bone aches (OR 2.06; 95% CI: 1.25, 3.42). The odds of developing a post-COVID-19 condition increased with the number of symptoms at infection. Females were more likely to report a post-COVID-19 condition (OR 1.54; 95% CI: 1.05, 2.24). Analyzing only non-hospitalized respondents changed results only slightly. Our study adds to growing evidence that even a mild course of COVID-19 poses a risk for developing a post-COVID-19 condition. Females and those with initial symptoms including fatigue, breathing difficulties, and cognitive symptoms seem more likely to also experience post COVID-19 symptoms several months after infection.KEY MESSAGESEven a mild course of COVID-19 poses a risk for developing a post-COVID-19 condition.Females seem more likely to develop a post-COVID-19 condition.Those with initial symptoms including fatigue, breathing difficulties, and cognitive symptoms seem more likely to develop a post-COVID-19 condition.

Identifiants

pubmed: 37337723
doi: 10.1080/07853890.2023.2226907
pmc: PMC10283437
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2226907

Références

EClinicalMedicine. 2021 Aug;38:101019
pubmed: 34308300
Nat Med. 2023 Jan;29(1):226-235
pubmed: 36456834
Eur J Epidemiol. 2022 May;37(5):539-548
pubmed: 35211871
PLoS One. 2021 Aug 26;16(8):e0256142
pubmed: 34437579
J Med Virol. 2022 Jan;94(1):253-262
pubmed: 34463956
Brain Behav Immun. 2022 Mar;101:93-135
pubmed: 34973396
Clin Microbiol Infect. 2022 May;28(5):657-666
pubmed: 35124265
J Womens Health (Larchmt). 2022 May;31(5):620-630
pubmed: 35333613
Nat Rev Microbiol. 2023 Mar;21(3):133-146
pubmed: 36639608
BMC Med. 2021 Sep 27;19(1):249
pubmed: 34565368
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Nat Commun. 2022 Oct 12;13(1):5663
pubmed: 36224173
Lancet Infect Dis. 2022 Apr;22(4):e102-e107
pubmed: 34951953
JAMA Netw Open. 2021 May 3;4(5):e2111417
pubmed: 34037731
Nat Commun. 2023 Apr 7;14(1):1948
pubmed: 37029117
Lancet Respir Med. 2022 Sep;10(9):863-876
pubmed: 35568052
EClinicalMedicine. 2021 May 24;36:100899
pubmed: 34036253
Lancet Reg Health Eur. 2021 Jul;6:100122
pubmed: 34027514
Fam Pract. 2022 Jan 19;39(1):159-167
pubmed: 34268556
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
Sci Rep. 2021 Aug 9;11(1):16144
pubmed: 34373540

Auteurs

Stefan Rach (S)

Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.

Lisa Kühne (L)

Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.

Hajo Zeeb (H)

Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
Faculty of Human and Health Sciences, University of Bremen, Bremen, Germany.

Wolfgang Ahrens (W)

Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.

Ulrike Haug (U)

Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
Faculty of Human and Health Sciences, University of Bremen, Bremen, Germany.

Hermann Pohlabeln (H)

Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH